# EDGAR Filing Document

**Accession Number:** 0001577524
**File Stem:** 0001140361-23-009098
**Filing Date:** 2023-2
**Character Count:** 5866
**Document Hash:** 5e05c4f34fdd338c41cb5e3a90e49fc5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-009098.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001140361-23-009098

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21392
- **FILM NUMBER:** 23680834

**BUSINESS ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sarissa Capital Management LP
- **CENTRAL INDEX KEY:** 0001577524
- **IRS NUMBER:** 900924432
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**BUSINESS ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 203-302-2330

**MAIL ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of the

#### Securities Exchange Act of 1934

Filed by the Registrant ☐ <br>

Filed by a party other than the Registrant ☒ <br>

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Definitive Additional Materials

☐ Soliciting Material under § 240.14a-12

## Amarin Corporation plc<br>

------

(Name of Registrant as Specified In Its Charter)

#### <br>

#### Sarissa Capital Catapult Fund LLC

#### Sarissa Capital Hawkeye Fund LP

#### ISP Fund LP

#### Sarissa Capital Offshore Master Fund LP

#### Sarissa Capital Master Fund II LP

#### Sarissa Capital Athena Fund Ltd

#### Atom Master Fund LP

#### Sarissa Capital Fund GP LP

#### Sarissa Capital Fund GP LLC

#### Sarissa Capital Offshore Fund GP LLC

#### Sarissa Capital Management GP LLC

#### Sarissa Capital Management LP

#### Alexander J. Denner, Ph.D.

#### Patrice Bonfiglio

#### Paul Cohen, M.D.

#### Mark DiPaolo

#### Keith L. Horn

#### Odysseas Kostas, M.D.

#### Louis Sterling III

#### Diane E. Sullivan

------

(Name of Person(s) Filing Proxy Statement, if other than the Registrant) <br>

Payment of Filing Fee (Check all boxes that apply):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

This filing contains a press release issued on February 28, 2023 by Sarissa Capital. <br>

------

 *#### SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE LANDSLIDE

#### Sarissa honored to have received 100 million more votes than Amarin board

Greenwich, CT, February 28, 2023 – Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin's largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.

Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa's rare and highly beneficial profile to unlock tremendous value for all shareholders.

#### LET'S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!

#### Additional Information

Sarissa Capital Management LP ("Sarissa Capital"), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the "Company") at the general meeting of the Company for the election of Sarissa Capital's slate of highly-qualified nominees (the "General Meeting"). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC's website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital's proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).

#FreeAmarin

Contact: Dayna Packes<br> Sarissa Capital Management LP<br> info@sarissacap.com*

------